Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis.
OBJECTIVE
To study the effect of mesenchymal stem cells (MSC) on experimental liver fibrosis in rats.


METHODS
MSC were derived from bone marrow obtained from femoral and tibial bones of male albino rats. MSC were separated, grown, and propagated in culture for 4 weeks and were characterized morphologically and by detection of CD29 by RT-PCR. They were then infused into the tail vein of female rats that received CCl4 injection to induce liver fibrosis. Rats were divided into 4 groups: control, CCl4, CCl4 plus MSC, and MSC. Liver tissue was examined histopathologically and liver functions (ALT and serum albumin) were estimated for all groups. Y-chromosome gene (sry) was assessed by PCR in liver tissue of the female rats to confirm uptake of the male stem cells. Hydroxyproline content in liver tissue was assessed by chemical methods and expression of the collagen gene (type I) was detected as a marker for liver fibrosis. Results of the present study showed that MSC have a significant antifibrotic effect as evidenced by the significant decrease in liver collagen gene expression as well as the decrease in hydroxyproline content in the CCl4/MSC group (p<0.001) compared to the CCl4 group. The Y-chromosome gene (sry) was detected by RT-PCR in the CCl4/MSC group, but was not detected in control group and other groups. The CD29 gene was expressed in MSC culture, and this confirmed the efficiency of isolation and propagation of MSC in culture. With regard to liver function, there was also a significant improvement and elevation of serum albumin in the CCl4/MSC group compared to the CCl4 group (p<0.05). As regard to the liver enzyme ALT, there was a decrease of its level in the CCl4/MSC group compared to the CCl4 group. However, this was statistically nonsignificant (p>0.05). In conclusion, MSC have a potential therapeutic effect against the fibrotic process through their effect in minimizing collagen deposition in addition to their capacity to differentiate into hepatocytes.
Abdel Aziz
M T
MT
Department of Medical Biochemistry, Unit of Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Eqypt. talaatbdaziz@yahoo.co.uk
Atta
H M
HM
Mahfouz
S
S
Fouad
H H
HH
Roshdy
N K
NK
Ahmed
H H
HH
Rashed
L A
LA
Sabry
D
D
Hassouna
A A
AA
Hasan
N M
NM
D000199:Actins / Q000235:genetics; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D064987:Cell- and Tissue-Based Therapy; D003094:Collagen / Q000235:genetics; D005260:Female; D005786:Gene Expression Regulation; D006909:Hydroxyproline / Q000378:metabolism; D008099:Liver / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008106:Liver Cirrhosis, Experimental / Q000503:physiopathology / Q000628:therapy*; D008111:Liver Function Tests; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D051381:Rats; D051876:Sex-Determining Region Y Protein / Q000235:genetics
D000199:Actins; D051876:Sex-Determining Region Y Protein; C497746:Sry protein, mouse; D003094:Collagen; D006909:Hydroxyproline